Successfully merged with Organogenesis Inc. • Now trading as ORGO
SPAC Overview
$300M
IPO Size
$3.6M
Trust (as of 2026-06-30)
Completed
Current Status
2016
IPO Year
Timeline Progress
About
Avista Healthcare Public Acquisition Corp. is a blank-check company formed to effect a merger or similar business combination with an unidentified target. Its initial focus is to acquire and operate a North American or European healthcare-related business.
Investment Focus
Healthcare
Geographic Focus
North America, Europe
The terms and the filing trail behind Avista Healthcare Public Acquisition Corp.
What the sponsor registered, what the deal actually priced at, and every 8-K that moved it — unit structure, sponsor promote, and the dated lifecycle events, each linked to its filing.
- Unit structure as registered and as priced — price, warrant coverage, rights, trust per unit
- Sponsor promote: founder shares and percentage, private-placement warrants, trust deposit
- The full 8-K lifecycle timeline, each event linked to its filing
- Price history across the unit, share and warrant tickers
- Follow it, and see it change on your watchlist
SPAC Team
Sponsors
Leadership
Arthur S. Leibowitz
Chair of Audit Committee, Director
Thompson Dean
Executive Chairman
Wayne D. Mackie
Chair of Compensation Committee, Director
David Frederick Burgstahler
Chief Executive Officer, Director, President
Gary S. Gillheeney Sr.
Chief Executive Officer, Director, President, President and Chief Executive Officer
Antonio S. Montecalvo
Health Policy and Contracting, Vice President
Lori Freedman
General Counsel, Vice President, Vice President and General Counsel
Henry Hagopian
Interim Chief Financial Officer
John Cafasso
Chief Financial Officer
Benjamin A. Silbert
General Counsel, Secretary
Brian Grow
Chief Commercial Officer
Patrick Bilbo
Chief Operating Officer
Alan A. Ades
Director
Albert Erani
Director
Brian A. Markison
Director
Charles Harwood
Director
David Erani
Director
Glenn H. Nussdorf
Director
Hakan Bjorklund
Director
Joshua Alexander Tamaroff
Director
Maurice Ades
Director
Robert Ades
Director
Robert P. O'Neil
Director
Michael W. Katz
Beneficial owner
Dennis Erani
Kenneth L. Horton
Extended Team Information
The team is affiliated with Avista, a middle-market private equity firm; its founders and managers have decades of private-equity experience, and the management team and board have extensive healthcare investing, operating, sourcing and acquisition experience.
Stock Performance
ORGO
Trading Symbol
First Trade
January 5, 2017
$9.85
At Merger
December 11, 2018
$10.15
+3%
6 Months Post-Merger
June 14, 2019
$7.33
-28%
1 Year Post-Merger
December 13, 2019
$4.90
-52%
2 Years Post-Merger
December 10, 2020
$4.86
-52%
Current Price
October 1, 2026
$1.40
-86%
Key Information
IPO Date
October 11, 2016
Total Redemptions
$314M
PIPE
$46M
State of Incorporation
DE
SIC
6770
Completion Date
December 10, 2018
Merger Target
Organogenesis Inc.
SPAC Ticker
AHPA
Merged Ticker
ORGO